drugset / Trial / NCT04546802
HepATocellular Cancer Hcv Therapy Study
Phase 3
Withdrawn
Bayside Health
Austin Hospital, Melbourne Australia · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Subjects with Hepatitis C Virus (HCV) infection, genotype 1 or 4 and with hepatocellular carcinoma (HCC) and a complete response to HCC therapy will be randomised to immediate or delayed (6 months) HCV therapy with Elbasvir (MK-8742) and Grazoprevir (MK-5172) \[EBR/GZR\].
Timeline
- Start
- 2019-09
- Primary completion
- 2021-06
- Completion
- 2023-06
Outcome
Outcome not reported
Stopped (Enrollment): “Recruitment will be too difficult due to available PBS funded treatment and recent Australian clinical guidelines will conflict with the premise of the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Elbasvir | Small molecule | — | Oral |
| Comparator | GRAZOPREVIR ANHYDROUS | Small molecule | — | Oral |